Comparative Pharmacology
Head-to-head clinical analysis: CORMAX versus FLUTEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORMAX versus FLUTEX.
CORMAX vs FLUTEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive effects. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine release.
Flutamide is a nonsteroidal antiandrogen that competitively inhibits the binding of dihydrotestosterone (DHT) to androgen receptors in target tissues, thereby blocking the androgenic effects.
2.5 mg orally twice daily; maximum 10 mg/day.
50 mg orally once daily
None Documented
None Documented
Terminal elimination half-life: 3.5 hours (range 2.5-4.5 h); clinical context: dosing every 4-6 hours to maintain therapeutic levels
Terminal elimination half-life: 24–36 hours, permitting once-daily dosing in chronic therapy
Renal: 90% unchanged; minor biliary/fecal: <5%
Renal: ~70% (50% unchanged, 20% as metabolites); Biliary/fecal: ~30%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid